Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2026
Broccoli Sprout Extract for Glycemic Management in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avesani Carla Maria, Swartling Oskar, Rosengren Anders H, Heimbürger Olof, Svensson Maria K, Guron Gregor, Segelmark Mårten, Petrauskiene Vaida, Lundberg Sigrid, Jonsson Andreas, Mörtberg Josefin, Bratt Oscar, Bonnevier Ursa, Fernstrom Anders, Uhlin Fredrik, Carlström Maria, Ghajavand Babak, Christensson Anders, Miyahira Roberta Fontanive, Evans Marie, Stenvinkel Peter, INITIATE study group and the SNephR Network
Аннотация
OBJECTIVE: Glucoraphanin, a precursor of sulforaphane (SFN), is found in high concentrations in broccoli sprout extract (BSE) and has been shown to have antioxidant effects and to improve glucose control in type 2 diabetes (T2D). This randomized controlled trial (RCT) aimed to investigate whether BSE could improve glucose control in patients with chronic kidney disease (CKD) and T2D.
DESIGN AND METHODS: This multicentre double-blind placebo-controlled RCT included adult patients with T2D and CKD stages 3b-4. Participants were randomized to receive an incremental dose of BSE (maximum 150 μmol/day BSE (750 μmol SFN)) or placebo. The use BSE or placebo lasted 12 weeks (week 1 to 13) plus 8 weeks (week 14 to 21) with no intervention. The main outcome was improvement in glycemic control.
RESULTS: 99 patients were included, and 91 completed the study. Mean age was 74±7 years, 69% men and mean estimated glomerular filtration rate (eGFR) 28±7 mL/min/1.73 m2. There were no significant differences in baseline characteristics between the groups. In an intention-to-treat analysis, there were no statistically significant differences between groups in fasting glucose, insulin or HbA1c levels after 13 weeks or at 21 weeks of follow-up (end of study). Similarly, no statistically significant differences were observed between both groups in these variables in a per protocol analysis.
CONCLUSION: In patients with T2D and moderate CKD, 12 weeks of treatment with BSE with progressing dose (50 to 150 μmol/day BSE) did not result in statistically significant changes in measures related with glycemic control.
DESIGN AND METHODS: This multicentre double-blind placebo-controlled RCT included adult patients with T2D and CKD stages 3b-4. Participants were randomized to receive an incremental dose of BSE (maximum 150 μmol/day BSE (750 μmol SFN)) or placebo. The use BSE or placebo lasted 12 weeks (week 1 to 13) plus 8 weeks (week 14 to 21) with no intervention. The main outcome was improvement in glycemic control.
RESULTS: 99 patients were included, and 91 completed the study. Mean age was 74±7 years, 69% men and mean estimated glomerular filtration rate (eGFR) 28±7 mL/min/1.73 m2. There were no significant differences in baseline characteristics between the groups. In an intention-to-treat analysis, there were no statistically significant differences between groups in fasting glucose, insulin or HbA1c levels after 13 weeks or at 21 weeks of follow-up (end of study). Similarly, no statistically significant differences were observed between both groups in these variables in a per protocol analysis.
CONCLUSION: In patients with T2D and moderate CKD, 12 weeks of treatment with BSE with progressing dose (50 to 150 μmol/day BSE) did not result in statistically significant changes in measures related with glycemic control.